Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones....

Related Keywords

New York ,United States ,American ,Maryc Beckerle ,Gail Eckhardt ,Michaelm Morrissey ,International Kidney Cancer Symposium ,Nasdaq ,Exchange Commission ,Extensive Drug Development ,Oncological Sciences ,Facebook ,Bristol Myers Squibb Company ,European Society For Medical Oncology ,Prostate Cancer Clinical Trials Working Group ,University Of Utah ,American Society Of Clinical Oncology ,Huntsman Cancer Institute ,Exelixis Inc ,Share Repurchase Program ,College Danl Duncan Comprehensive Cancer Center ,Takeda Pharmaceutical Company ,Translational Research ,Arcus Biosciences Inc ,National Cancer Institute ,Alliance For Clinical Trials In Oncology ,Drug Administration ,Conference Call ,Announces Fourth Quarter ,Fiscal Year ,Provides Corporate ,Chief Executive Officer ,Investigational New Drug ,Ipsen Pharma ,Accepted Accounting Principles ,Franchise Net Product Revenues ,Trial Evaluating Cabozantinib ,Advanced Pancreatic ,Extra Pancreatic Neuroendocrine Tumors ,Medical Oncology ,Clinical Trials ,Safety Monitoring Board ,Metastatic Castration Resistant Prostate Cancer ,American Society ,Clinical Oncology ,Cancers Symposium ,Year Follow Up Results ,Previously Untreated Renal Cell Carcinoma ,Encouraging Results ,Expansion Cohort ,Evaluating Zanzalintinib ,Advanced Kidney Cancer ,Arcus Biosciences ,Enter Clinical Trial Collaboration ,Evaluate Zanzalintinib ,Trial Evaluating Zanzalintinib ,Previously Untreated Recurrent ,Metastatic Head ,Provides Strategic Review ,Small Molecule Pipeline ,Event Calendar ,Two New Board Members ,Corporate Governance ,Exelixis Board ,Distinguished Professor ,Associate Dean ,Experimental Therapeutics ,Baylor College ,Associate Director ,Comprehensive Cancer ,Key Priorities ,Anticipated Milestones ,Abbreviated New Drug Application ,Investigational New Drug Applications ,Annual Report ,Quarterly Reports ,Bristol Myers Squibb ,Accounting Standards Codification Topic ,